A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Recruiting now · Phase 1

Conditions studied: Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma

In brief

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Key facts

Study ID

NCT07226843

Run by

Eli Lilly and Company

People needed

460

Starts

2026-04-17

Expected to finish

2030-02-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:
• Diffuse large B-cell lymphoma - not otherwise specified
• High-grade B-cell lymphoma
• Diffuse large B-cell lymphoma - transformed from indolent lymphomas
• Follicular large B-cell lymphoma
• Follicular lymphoma
• Other non-Hodgkin lymphoma
• Has measurable disease
• Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy

You may not qualify if…

• Has an active second cancer
• Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.
• Has known Cytomegalovirus infection. Participants with negative status are eligible
• Has known hepatitis B or C infection or uncontrolled HIV
• Has known significant heart disease

Where it is running

• The Ohio State University (OSU) — Columbus, Ohio, United States (enrolling)
• City of Hope — Duarte, California, United States (enrolling)
• Sarah Cannon Research Institute — Nashville, Tennessee, United States (enrolling)
• Vanderbilt University Medical Center — Nashville, Tennessee, United States (enrolling)
• Texas Oncology - DFW (Sammons CC) — Dallas, Texas, United States (enrolling)
• Colorado Blood Cancer Institute — Denver, Colorado, United States (enrolling)
• University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance) — Seattle, Washington, United States (enrolling)
• Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
• University of Miami - Sylvester Cancer Center — Miami, Florida, United States (enrolling)
• Florida Cancer Specialists - Sarasota — Sarasota, Florida, United States (enrolling)
• Emory University Hospital — Atlanta, Georgia, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Mayo Clinic - Rochester — Rochester, Minnesota, United States (enrolling)
• Columbia University — New York, New York, United States (enrolling)
• University of Rochester — Rochester, New York, United States (enrolling)
• Mayo Clinic - Scottsdale — Scottsdale, Arizona, United States (enrolling)
• Okayama University Hospital — Okayama, Japan
• Cancer Institute Hospital of JFCR — Tokyo, Japan
• Pratia Onkologia Katowice — Katowice, Poland
• Pratia MCM Krakow — Krakow, Poland
• AIDPORT Sp. z o.o. — Skorzewo, Poland
• Instytut Hematologii i Transfuzjologii w Warszawie — Warsaw, Poland
• Institut Catala d'Oncologia - L'Hospitalet — Barcelona, Spain
• South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.